Drug Profile


Alternative Names: P 0005672; P 005672; WC-3035

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Paratek Pharmaceuticals
  • Developer Actavis; Allergan
  • Class Amides; Antiacnes; Antibacterials; Naphthacenes; Skin disorder therapies; Small molecules; Tetracyclines
  • Mechanism of Action Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Phase II Rosacea

Most Recent Events

  • 01 Feb 2017 Allergan completes a phase III trial in Acne vulgaris (In children, In adolescents, In adults) in USA (PO, tablets) (NCT02320149)
  • 01 Aug 2016 Allergan completes a phase III trial in Acne vulgaris (In Children, In Adolescents, In adults) in USA (NCT02413346)
  • 09 Mar 2016 Paratek Pharmaceuticals has patent protection for sarecycline in USA (Paratek Pharmaceuticals, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top